Sarcoidosis

Chronic Respiratory Disease

Volumn 7, Issue 4, 2010, Pages 247-258

  De Boer, Sally ^a   Wilsher, Margaret ^a  

^a AUCKLAND DISTRICT HEALTH BOARD   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BUDESONIDE; CHLORAMBUCIL; CHLOROQUINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; GAMMA INTERFERON; HYDROXYCHLOROQUINE; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2; METHOTREXATE; PENTOXIFYLLINE; PLACEBO; PREDNISOLONE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

CLINICAL FEATURE; CLINICAL TRIAL; CYTOKINE RELEASE; DEMYELINATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; EYE DISEASE; FOLLOW UP; HEART DISEASE; HUMAN; IMMUNOPATHOLOGY; INFECTION; LUNG ASPERGILLOSIS; LUNG FUNCTION; LUNG SARCOIDOSIS; MORBIDITY; NEOPLASM; NEUROLOGIC DISEASE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RESPIRATORY TRACT DISEASE; REVIEW; SEX DIFFERENCE; SKIN DISEASE; UNSPECIFIED SIDE EFFECT; PATHOPHYSIOLOGY; SARCOIDOSIS;

HUMANS; PROGNOSIS; SARCOIDOSIS, PULMONARY;

EID: 78649660856     PISSN: 14799723     EISSN: 14799731     Source Type: Journal    
DOI: 10.1177/1479972310388352     Document Type: Review

References (121)

1. Boeck C. Multiple benign sarkoid of the skin. J Cutan Genitourinary Dis 1899 ; 17: 543-550.
2. Scadding JG and Mitchell DN Sarcoidosis. London: Chapman and Hall Ltd ; 1985.
3. Hosoda Y., Yamaguchi M., Hiraga Y. Global epidemiology of sarcoidosis. What story do prevalence and incidence tell us? Clinics in Chest Medicine 1997 ; 18: 681-694.
4. Rybicki BA, Iannuzzi MC, Rybicki BA, Iannuzzi MC Epidemiology of sarcoidosis: recent advances and future prospects. Semin 2007 ; 28: 22-35.
5. Iannuzzi MC Advances in the genetics of sarcoidosis. Proc Am Thorac Soc 2007 ; 4: 457-460.
6. Valeyre D., Uzunhan Y., Bouvry D., Naccache JM, Nunes H. Up-to-date in pulmonary and extrapulmonary sarcoidosis. Acta Clin Belg 2008 ; 63: 408-413.
7. Baughman RP, Teirstein A., Judson MA, Rossman M., Yeager H., Jr, Bresnitz E., et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001 ; 164: 1885-1889.
8. Wilsher ML Seasonal clustering of sarcoidosis presenting with erythema nodosum. Eur Respir J 1998 ; 12: 1197-1199.
9. Demirkok SS, Basaranoglu M., Akbilgic O. Seasonal variation of the onset of presentations in stage 1 sarcoidosis. Int J Clin Pract 2006 ; 60: 1443-1450.
10. Demirkok SS, Basaranoglu M., Coker E., Karayel T. Seasonality of the onset of symptoms, tuberculin test anergy and kveim positive reaction in a large cohort of patients with sarcoidosis. Respirology 2007 ; 12: 591-593.
11. Barnard J., Rose C., Newman L., Canner M., Martyny J., McCammon C., et al. Job and industry classifications associated with sarcoidosis in a case-control etiologic study of sarcoidosis (access). J Occup Environ Med 2005 ; 47: 226-234.
12. Brown ST, Brett I., Almenoff PL, Lesser M., Terrin M., Teirstein AS, et al. Recovery of cell wall-deficient organisms from blood does not distinguish between patients with sarcoidosis and control subjects.[see comment]. Chest 2003 ; 123: 413-417.
13. Vokurka M., Lecossier D., du Bois RM, Wallaert B., Kambouchner M., Tazi A., et al. Absence of DNA from mycobacteria of the m. Tuberculosis complex in sarcoidosis. Am J Respir Crit Care Med 1997 ; 156: 1000-1003.
14. Wilsher ML, Menzies RE, Croxson MC Mycobacterium tuberculosis DNA in tissues affected by sarcoidosis. Thorax 1998 ; 53: 871-874.
15. Yasuhara T., Tada R., Nakano Y., Tei M., Mochida C., Kamei M., et al. The presence of propionibacterium spp. In the vitreous fluid of uveitis patients with sarcoidosis. Acta Ophthalmol Scand 2005 ; 83: 364-369.
16. du Bois RM, Goh N., McGrath D., Cullinan P. Is there a role for microorganisms in the pathogenesis of sarcoidosis? J Int Med 2003 ; 253: 4-17.
17. Gupta D., Agarwal R., Aggarwal AN, Jindal SK Molecular evidence for the role of mycobacteria in sarcoidosis: a meta-analysis. Eur Respir J 2007 ; 30: 508-516.
18. Rybicki BA, Iannuzzi MC, Frederick MM, Thompson BW, Rossman MD, Bresnitz EA, et al. Familial aggregation of sarcoidosis. A case-control etiologic study of sarcoidosis (access). Am J Respir Crit Care Med 2001 ; 164: 2085-2091.
19. Grunewald J., Grunewald J. Genetics of sarcoidosis. Curr Opin Pulmon Med 2008 ; 14: 434-439.
20. Rybicki BA, Iannuzzi MC Epidemiology of sarcoidosis: Recent advances and future prospects. Semin Respir Crit Care Med 2007 ; 28: 22-35.
21. Spagnolo P., du Bois RM, Spagnolo P., du Bois RM Genetics of sarcoidosis. Clin Dermatol 2007 ; 25: 242-249.
22. Rossman MD, Thompson B., Frederick M., Iannuzzi MC, Rybicki BA, Pander JP, et al. Hla and environmental interactions in sarcoidosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases 2008 ; 25: 125-132.
23. Izbicki G., Chavko R., Banauch GI, Weiden MD, Berger KI, Aldrich TK, et al. World trade center ''Sarcoid-like'' Granulomatous pulmonary disease in New York city fire department rescue workers.[see comment]. Chest 2007 ; 131: 1414-1423.
24. Prezant DJ, Dhala A., Goldstein A., Janus D., Ortiz F., Aldrich TK, et al. The incidence, prevalence, and severity of sarcoidosis in New York city firefighters. Chest 1999 ; 116: 1183-1193.
25. Hill TA, Lightman S., Pantelidis P., Abdallah A., Spagnolo P., du Bois RM Intracellular cytokine profiles and t cell activation in pulmonary sarcoidosis. Cytokine 2008 ; 42: 289-292.
26. Zissel G., Prasse A., Muller-Quernheim J., Zissel G., Prasse A., Muller-Quernheim J. Sarcoidosis-immunopathogenetic concepts. Semin 2007 ; 28: 3-14.
27. Fehervari Z., Sakaguchi S., Fehervari Z., Sakaguchi S. Cd4+ tregs and immune control. J Clin Invest 2004 ; 114: 1209-1217.
28. Shigehara K., Shijubo N., Ohmichi M., Takahashi R., Kon S., Okamura H., et al. Il-12 and il-18 are increased and stimulate ifn-gamma production in sarcoid lungs. J Immunol 2001 ; 166: 642-649.
29. Grunewald J., Eklund A., Grunewald J., Eklund A. Role of cd4+ t cells in sarcoidosis. Proc Am Thorac Soc 2007 ; 4: 461-464.
30. Grunewald J., Wahlstrom J., Berlin M., Wigzell H., Eklund A., Olerup O. Lung restricted t cell receptor av2s3+ cd4+ t cell expansions in sarcoidosis patients with a shared hla-drbeta chain conformation. Thorax 2002 ; 57: 348-352.
31. Esin S., Batoni G., Saruhan-Direskeneli G., Harris RA, Grunewald J., Pardini M., et al. In vitro expansion of t-cell-receptor valpha2.3(+) cd4(+) t lymphocytes in hla-dr17(3), dq2(+) individuals upon stimulation with mycobacterium tuberculosis. Infect Immun 1999 ; 67: 3800-3809.
32. Chen ES, Wahlstrom J., Song Z., Willett MH, Wiken M., Yung RC, et al. T cell responses to mycobacterial catalase-peroxidase profile a pathogenic antigen in systemic sarcoidosis. J Immunol 2008 ; 181: 8784-8796.
33. Boyton RJ, Altmann DM, Wright A., Kon OM, Boyton RJ, Altmann DM, et al. Pulmonary infection with cryptococcus neoformans in the face of underlying sarcoidosis. Respiration 2007 ; 74: 462-466.
34. Mayock RL, Bertrand P., Morrison CE, Scott JH Manifestations of sarcoidosis. Analysis of 145 patients, with a review of nine series selected from the literature. Am J Med 1963 ; 35: 67-89.
35. Reich JM, Johnson RE Course and prognosis of sarcoidosis in a nonreferral setting. Analysis of 86 patients observed for 10 years. Am J Med 1985 ; 78: 61-67.
36. Sipahi Demirkok S., Basaranoglu M., Dervis E., Bal M., Karayel T. Analysis of 87 patients with lofgren's syndrome and the pattern of seasonality of subacute sarcoidosis. Respirology 2006 ; 11: 456-461.
37. Michielsen HJ, Peros-Golubicic T., Drent M., De Vries J. Relationship between symptoms and quality of life in a sarcoidosis population. Respiration 2007 ; 74: 401-405.
38. Sharma OP Fatigue and sarcoidosis [comment]. Eur Respir J 1999 ; 13: 713-714.
39. Michielsen HJ, Drent M., Peros-Golubicic T., De Vries J. Fatigue is associated with quality of life in sarcoidosis patients. Chest 2006 ; 130: 989-994.
40. Drent M., Wirnsberger RM, de Vries J., van Dieijen-Visser MP, Wouters EF, Schols AM Association of fatigue with an acute phase response in sarcoidosis [see comment]. Eur Respir J 1999 ; 13: 718-722.
41. Lynch JP, 3rd, Ma YL, Koss MN, White ES Pulmonary sarcoidosis. Semin 2007 ; 28: 53-74.
42. Cox CE, Donohue JF, Brown CD, Kataria YP, Judson MA Health-related quality of life of persons with sarcoidosis. Chest 2004 ; 125: 997-1004.
43. Scadding J. Prognosis of intrathoracic sarcoidosis in England: A review of 136 cases after five years' observation. British medical journal 1961 ; 2: 1165-1172.
44. Halme M., Piilonen A., Taskinen E. Comparison of endobronchial and transbronchial biopsies with high-resolution ct (hrcit) in the diagnosis of sarcoidosis. APMIS 2001 ; 109: 289-294.
45. Akira M., Kozuka T., Inoue Y., Sakatani M. Long-term follow-up ct scan evaluation in patients with pulmonary sarcoidosis. Chest 2005 ; 127: 185-191.
46. Brauner MW, Lenoir S., Grenier P., Cluzel P., Battesti JP, Valeyre D. Pulmonary sarcoidosis: Ct assessment of lesion reversibility. Radiology 1992 ; 182: 349-354.
47. Brauner MW, Grenier P., Mompoint D., Lenoir S., de Cremoux H. Pulmonary sarcoidosis: evaluation with high-resolution ct. Radiology 1989 ; 172: 467-471.
48. Muller NL, Mawson JB, Mathieson JR, Abboud R., Ostrow DN, Champion P. Sarcoidosis: correlation of extent of disease at ct with clinical, functional, and radiographic findings. Radiology 1989 ; 171: 613-618.
49. Hansell DM, Milne DG, Wilsher ML, Wells AU Pulmonary sarcoidosis: morphologic associations of airflow obstruction at thin-section ct. Radiology 1998 ; 209: 697-704.
50. Drent M., De Vries J., Lenters M., Lamers RJS, Rothkranz-Kos S., Wouters EFM, van Dieijen-Visser MP, Verschakelen JA Sarcoidosis: assessment of disease severity using HRCT. Eur Radiol 2003 ; 13: 2462-2471.
51. Winterbauer RH, Hutchinson JF Use of pulmonary function tests in the management of sarcoidosis. Chest 1980 ; 78: 640-647.
52. Harrison BD, Shaylor JM, Stokes TC, Wilkes AR Airflow limitation in sarcoidosis-a study of pulmonary function in 107 patients with newly diagnosed disease. Respir Med 1991 ; 85: 59-64.
53. Bechtel JJ, Starr T., 3rd, Dantzker DR, Bower JS Airway hyperreactivity in patients with sarcoidosis. Am Rev Respir Dis 1981 ; 124: 759-761.
54. Baughman RP, Sparkman BK, Lower EE Six-minute walk test and health status assessment in sarcoidosis. Chest 2007 ; 132: 207-213.
55. Battesti JP, Georges R., Basset F., Saumon G. Chronic cor pulmonale in pulmonary sarcoidosis. Thorax 1978 ; 33: 76-84.
56. Neville E., Walker AN, James DG Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med 1983 ; 52: 525-533.
57. Handa T., Nagai S., Miki S., Fushimi Y., Ohta K., Mishima M., et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest 2006 ; 129: 1246-1252.
58. Shorr AF, Davies DB, Nathan SD Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest 2003 ; 124: 922-928.
59. Shorr AF, Helman DL, Davies DB, Nathan SD Pulmonary hypertension in advanced sarcoidosis: Epidemiology and clinical characteristics. Eur Respir J 2005 ; 25: 783-788.
60. Nunes H., Humbert M., Capron F., Brauner M., Sitbon O., Battesti JP, et al. Pulmonary hypertension associated with sarcoidosis: Mechanisms, haemodynamics and prognosis. Thorax 2006 ; 61: 68-74.
61. Sulica R., Teirstein AS, Kakarla S., Nemani N., Behnegar A., Padilla ML, et al. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest 2005 ; 128: 1483-1489.
62. Arcasoy SM, Christie JD, Ferrari VA, Sutton MSJ, Zisman DA, Blumenthal NP, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003 ; 167: 735-740.
63. Kuriyama K., Gamsu G., Stern RG, Cann CE, Herfkens RJ, Brundage BH Ct-determined pulmonary artery diameters in predicting pulmonary hypertension. Invest Radiol 1984 ; 19: 16-22.
64. Ng CS, Wells AU, Padley SP A ct sign of chronic pulmonary arterial hypertension: The ratio of main pulmonary artery to aortic diameter. J Thorac Imaging 1999 ; 14: 270-278.
65. Judson MA, Baughman RP, Teirstein AS, Terrin ML, Yeager H., Jr. Defining organ involvement in sarcoidosis: The access proposed instrument. Access research group. A case control etiologic study of sarcoidosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases 1999 ; 16: 75-86.
66. Society AT Statement on sarcoidosis. Am J Respir Crit Care Med 1999 ; 160: 736-755.
67. Wilsher ML, Hopkins R., Young LM, Cornere M., West T. Characteristics of sarcoidosis in maori and pacific islanders. Am J Respir Crit Care Med 2005 ; 171 (supplement): A864.
68. Ohara K., Judson M., Baughman R. Clinical aspects of ocular sarcoidosis. Eur Respir Monogr 2005 ; 32: 188-209.
69. Sharma OP, Maheshwari A., Thaker K. Myocardial sarcoidosis. Chest 1993 ; 103: 253-258.
70. Silverman KJ, Hutchins GM, Bulkley BH Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 1978 ; 58: 1204-1211.
71. Uemura A., Morimoto S., Hiramitsu S., Kato Y., Ito T., Hishida H. Histologic diagnostic rate of cardiac sarcoidosis: Evaluation of endomyocardial biopsies. Am Heart J 1999 ; 138: 299-302.
72. Yamagishi H., Shirai N., Takagi M., Yoshiyama M., Akioka K., Takeuchi K., et al. Identification of cardiac sarcoidosis with (13)n-nh(3)/(18)f-fdg pet [see comment]. J Nucl Med 2003 ; 44: 1030-1036.
73. Sharma OP Neurosarcoidosis: a personal perspective based on the study of 37 patients. Chest 1997 ; 112: 220-228.
74. Roethe RA, Fuller PB, Byrd RB, Hafermann DR Transbronchoscopic lung biopsy in sarcoidosis. Optimal number and sites for diagnosis. Chest 1980 ; 77: 400-402.
75. Poe RH, Israel RH, Utell MJ, Hall WJ Probability of a positive transbronchial lung biopsy result in sarcoidosis. Arch Intern Med 1979 ; 139: 761-763.
76. de Boer S., Milne DG, Zeng I., Wilsher ML Does ct scanning predict the likelihood of a positive transbronchial biopsy in sarcoidosis? Thorax 2009 ; 64: 436-439.
77. Shorr AF, Torrington KG, Hnatiuk OW Endobronchial biopsy for sarcoidosis: a prospective study. Chest 2001 ; 120: 109-114.
78. Wildi SM, Judson MA, Fraig M., Fickling WE, Schmulewitz N., Varadarajulu S., et al. Is endosonography guided fine needle aspiration (EUS-FNA) for sarcoidosis as good as we think? Thorax 2004 ; 59: 794-799.
79. Wong M., Yasufuku K., Nakajima T., Herth FJF, Sekine Y., Shibuya K., et al. Endobronchial ultrasound: New insight for the diagnosis of sarcoidosis [see comment]. Eur Respir J 2007 ; 29: 1182-1186.
80. Garwood S., Judson MA, Silvestri G., Hoda R., Fraig M., Doelken P. Endobronchial ultrasound for the diagnosis of pulmonary sarcoidosis [see comment]. Chest 2007 ; 132: 1298-1304.
81. Annema JT, Veselic M., Rabe KF Endoscopic ultrasound-guided fine-needle aspiration for the diagnosis of sarcoidosis [see comment]. Eur Respir J 2005 ; 25: 405-409.
82. Biller H., Zissel G., Ruprecht B., Nauck M., Busse Grawitz A., Muller-Quernheim J. Genotype-corrected reference values for serum angiotensin-converting enzyme. Eur Respir J 2006 ; 28: 1085-1090.
83. Lieberman J., Schleissner LA, Nosal A., Sastre A., Mishkin FS Clinical correlations of serum angiotensin-converting enzyme (ace) in sarcoidosis. A longitudinal study of serum ace, 67gallium scans, chest roentgenograms, and pulmonary function. Chest 1983 ; 84: 522-528.
84. Costabel U. Cd4/cd8 ratios in bronchoalveolar lavage fluid: of value for diagnosing sarcoidosis? [comment]. Eur Respir J 1997 ; 10: 2699-2700.
85. Paramothayan NS, Lasserson TJ, Jones P. Corticosteroids for pulmonary sarcoidosis. Cochrane Database of Systematic Reviews 2009 ; 1.
86. Wells AU, Hirani N., British Thoracic Society Interstitial Lung Disease Guideline Group BTSSoCC, Thoracic Society of A, New Zealand Thoracic S, Irish Thoracic S. Interstitial lung disease guideline: The British thoracic society in collaboration with the thoracic society of Australia and New Zealand and the Irish thoracic society. Thorax 2008 ; 63 (suppl 5). v1-58.
87. Gibson GJ, Prescott RJ, Muers MF, Middleton WG, Mitchell DN, Connolly CK, et al. British thoracic society sarcoidosis study: effects of long term corticosteroid treatment [see comment]. Thorax 1996 ; 51: 238-247.
88. Selroos O., Lofroos AB, Pietinalho A., Niemisto M., Riska H. Inhaled budesonide for maintenance treatment of pulmonary sarcoidosis. Sarcoidosis 1994 ; 11: 126-131.
89. Gottlieb JE, Israel HL, Steiner R Mea. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest 11997 ; 111: 623-631.
90. Alberts C., van der Mark TW, Jansen HM Inhaled budesonide in pulmonary sarcoidosis: A double blind, placebo controlled study. Dutch study group on pulmonary sarcoidosis. Eur Respir J 1995 ; 8: 682-688.
91. Dev S., McCallum RM, Jaffe GJ Methotrexate treatment for sarcoid-associated panuveitis. Ophthalmology 1999 ; 106: 111-118.
92. Lower EE, Baughman RP Prolonged use of methotrexate for sarcoidosis. Arch Intern Med 1995 ; 155: 846-851.
93. Smith JR, Rosenbaum JT A role for methotrexate in the management of non-infectious orbital inflammatory disease. Br J Ophthalmol 2001 ; 85: 1220-1224.
94. Vucinic VM, Vucinic VM What is the future of methotrexate in sarcoidosis? A study and review. Curr Opin Pulmon Med 2002 ; 8: 470-476.
95. Lewis SJ, Ainslie GM, Bateman ED Efficacy of azathioprine as second-line treatment in pulmonary sarcoidosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases 1999 ; 16: 87-92.
96. Muller-Quernheim J., Kienast K., Held M., Pfeifer S., Costabel U. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen [see comment]. Eur Respir J 1999 ; 14: 1117-1122.
97. Baughman RP, Winget DB, Lower EE Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasculitis and Diffuse Lung Diseases 2000 ; 17: 60-66.
98. Anonymous. Chloroquine in the treatment of sarcoidosis. A report from the research committee of the British tuberculosis association. Tubercle 1967 ; 48: 257-272.
99. Baltzan M., Mehta S., Kirkham TH, Cosio MG Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med 1999 ; 160: 192-197.
100. Doty JD, Mazur JE, Judson MA, Doty JD, Mazur JE, Judson MA Treatment of corticosteroid-resistant neurosarcoidosis with a short-course cyclophosphamide regimen. Chest 2003 ; 124: 2023-2026.
101. Israel HL, McComb BL Chlorambucil treatment of sarcoidosis. Sarcoidosis 1991 ; 8: 35-41.
102. Kataria YP Chlorambucil in sarcoidosis. Chest 1980 ; 78: 36-43.
103. Paramothayan S., Lasserson T., Walters EH Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis.[update in cochrane database syst rev. 2006 ; 3: Cd003536 ; pmid: 16856012]. Cochrane Database of Systematic Reviews 2003: CD003536.
104. Wyser CP, van Schalkwyk EM, Alheit B., Bardin PG, Joubert JR Treatment of progressive pulmonary sarcoidosis with cyclosporin a. A randomized controlled trial [see comment]. Am J Respir Crit Care Med 1997 ; 156: 1371-1376.
105. York EL, Kovithavongs T., Man SF, Rebuck AS, Sproule BJ Cyclosporine and chronic sarcoidosis. Chest 1990 ; 98: 1026-1029.
106. Zabel P., Entzian P., Dalhoff K., Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med 1997 ; 155: 1665-1669.
107. Baughman RP, Judson MA, Teirstein AS, Moller DR, Lower EE, Baughman RP, et al. Thalidomide for chronic sarcoidosis. Chest 2002 ; 122: 227-232.
108. Barnabe C., McMeekin J., Howarth A., Martin L., Barnabe C., McMeekin J., et al. Successful treatment of cardiac sarcoidosis with infliximab. J Rheumatol 2008 ; 35: 1686-1687.
109. Baughman RP, Bradley DA, Lower EE Infliximab in chronic ocular inflammation. Int J Clin Pharmacol Therapeut 2005 ; 43: 7-11.
110. Hoitsma E., Faber CG, van Santen-Hoeufft M., De Vries J., Reulen JP, Drent M., et al. Improvement of small fiber neuropathy in a sarcoidosis patient after treatment with infliximab. Sarcoidosis Vasculitis and Diffuse Lung Diseases 2006 ; 23: 73-77.
111. Moravan M., Segal BM, Moravan M., Segal BM Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil. Neurology 2009 ; 72: 337-340.
112. Pritchard C., Nadarajah K. Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients. Ann Rheumatic Dis 2004 ; 63: 318-320.
113. Saleh S., Ghodsian S., Yakimova V., Henderson J., Sharma OP, Saleh S., et al. Effectiveness of infliximab in treating selected patients with sarcoidosis. Respir Med 2006 ; 100: 2053-2059.
114. Stagaki E., Mountford WK, Lackland DT, Judson MA, Stagaki E., Mountford WK, et al. The treatment of lupus pernio: Results of 116 treatment courses in 54 patients. Chest 2009 ; 135: 468-476.
115. Baughman RP, Drent M., Kavuru M., Judson MA, Costabel U., du Bois R., et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006 ; 174: 795-802.
116. Judson MA, Baughman RP, Costabel U., Flavin S., Lo KH, Kavuru MS, et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J 2008 ; 31: 1189-1196.
117. Caviglia R., Boskoski I., Cicala M., Caviglia R., Boskoski I., Cicala M. Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues. Expert Opin Drug Saf 2008 ; 7: 617-632.
118. Judson MA Lung transplantation for pulmonary sarcoidosis. Eur Respir J 1998 ; 11: 738-734.
119. Shorr AF, Helman DL, Davies DB, Nathan SD, Shorr AF, Helman DL, et al. Sarcoidosis, race, and short-term outcomes following lung transplantation. Chest 2004 ; 125: 990-996.
120. Barnett CF, Bonura EJ, Nathan SD, Ahmad S., Shlobin OA, Osei K., et al. Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience [see comment]. Chest 2009 ; 135: 1455-1461.
121. Hamilton-Craig CR, Slaughter R., McNeil K., Kermeen F., Walters DL Improvement after angioplasty and stenting of pulmonary arteries due to sarcoid mediastinal fibrosis. Heart, Lung and Circulation 2009 ; 18: 222-225.